Department of Research & Evaluation, SC Kaiser Permanente

Research Scientists

Reina Haque, PhD, MPH

Research Scientist III
Research & Evaluation
100 S. Los Robles Ave
Pasadena, CA 91101-2453
Phone: 626-564-5707
Email Address: Reina.Haque@kp.org

Back to Research Scientists Team

Other Affiliation

Scientific Advisor, Cancer Registry, Clinical Analysis

Education

PhD, Epidemiology, University of California at Berkeley, Berkeley, California

MPH, Environmental Health Sciences, University of California at Los Angeles, Los Angeles, California

BS, Psychobiology, University of California at Los Angeles, Los Angeles, California

Research Interests

Dr. Haque's research interests include pharmacoepidemiology and cancer risk, detection and screening for cancer, broad areas of cancer epidemiology including molecular markers of fatal prostate cancer and breast cancer prognosis, and survivorship among cancer patients.

Publications Studies

Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X, Chlebowski RT, Shi J, Barac A, Haque R
Breast Cancer Res Treat. 2019; : PubMed Abstract

Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured Women.
Haque R, Xu X, Shi J, Kwan ML, Chlebowski RT
Ethn Dis. 2018; 28:565-574 PubMed Abstract

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
Sehrawat A, Gao L, Wang Y, Bankhead A, McWeeney SK, King CJ, Schwartzman J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Kim DH, Sampson DA, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Sharma S, Bearss J, Beer TM, Thomas GV, Heiser LM, Alumkal JJ
Proc Natl Acad Sci U S A. 2018; 115:E4179-E4188 PubMed Abstract

Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma.
Chao C, Silverberg MJ, Chen LH, Xu L, Martínez-Maza O, Abrams DI, Zha HD, Haque R, Said J
Leuk Lymphoma. 2018; 59:321-329 PubMed Abstract

Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer.
Bradley MC, Zhou Y, Freedman AN, Yood MU, Quesenbery CP, Haque R, Van Den Eeden SK, Cassidy-Bushrow AE, Aaronson D, Potosky AL
Cancer Causes Control. 2018; 29:785-791 PubMed Abstract

Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL
J Urol. 2017; 197:1448-1454 PubMed Abstract

Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.
Haque R, Shi J, Chung J, Xu X, Avila C, Campbell C, Ahmed SA, Chen L, Schottinger JE
J Am Pharm Assoc. 2017; 57:303-310.e2 PubMed Abstract

Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.
Griggs JJ, Hamilton AS, Schwartz KL, Zhao W, Abrahamse PH, Thomas DG, Jorns JM, Jewell R, Saber ME, Haque R, Katz SJ
Breast Cancer Res Treat. 2017; 161:375-384 PubMed Abstract

Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Haque R, UlcickasYood M, Xu X, Cassidy-Bushrow AE, Tsai HT, Keating NL, Van Den Eeden SK, Potosky AL
Br J Cancer. 2017; 117:1233-1240 PubMed Abstract

Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, Thomson CA, Howard BV, Wactawski-Wende J, Chen C, Rohan TE, Simon MS, Reed SD, Manson JE
J Natl Cancer Inst. 2016; 108 PubMed Abstract

Cardiovascular Disease After Aromatase Inhibitor Use.
Haque R, Shi J, Schottinger JE, Chung J, Avila C, Amundsen B, Xu X, Barac A, Chlebowski RT
JAMA Oncol. 2016; 2:1590-1597 PubMed Abstract

Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
Kwan ML, Shi JM, Habel LA, Song J, Chung JW, Avila CC, Schottinger JE, Cheetham TC, Fletcher SW, Haque R
Breast Cancer Res Treat. 2016; 156:379-389 PubMed Abstract

Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, Avila C, Kleinman K, Habel LA, Fletcher SW, Kwan ML
J Natl Cancer Inst. 2016; 108 PubMed Abstract

Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Van Den Eeden SK, Cassidy-Bushrow AE, Zhou Y, Keating NL, Smith MR, Aaronson DS, Potosky AL
World J Urol. 2016; 34:1611-1619 PubMed Abstract

Treatment patterns for ductal carcinoma in situ from 2000-2010 across six integrated health plans.
Feigelson HS, Carroll NM, Weinmann S, Haque R, Yu CL, Butler MG, Waitzfelder B, Wrenn MG, Capra A, McGlynn EA, Habel LA
Springerplus. 2015; 4:24 PubMed Abstract

Statins and hip fracture risk in men: a population-based case-control study.
Adams AL, Shi JM, Reynolds K, Haque R, Cheetham TC, Kawatkar AA, Fithian DC, Jacobsen SJ
Ann Epidemiol. 2015; 25:844-8 PubMed Abstract

Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study.
Collins LC, Achacoso N, Haque R, Nekhlyudov L, Quesenberry CP, Schnitt SJ, Habel LA, Fletcher SW
Ann Surg Oncol. 2015 PubMed Abstract

Metformin and breast and gynecological cancer risk among women with diabetes.
Soffer D, Shi J, Chung J, Schottinger JE, Wallner LP, Chlebowski RT, Lentz SE, Haque R
BMJ Open Diabetes Res Care. 2015; 3:e000049 PubMed Abstract

Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT, Schottinger JE, Shi J, Chung J, Haque R
Cancer. 2015; 121:2147-55 PubMed Abstract

A Comparative Study of Molecular Characteristics of Diffuse Large B-cell Lymphoma from Patients with and without Human Immunodeficiency Virus Infection.
Chao C, Silverberg MJ, Xu L, Chen LH, Castor B, Martínez-Maza O, Abrams DI, Zha HD, Haque R, Said J
Clin Cancer Res. 2015; 21:1429-37 PubMed Abstract

A hybrid approach to identify subsequent breast cancer using pathology and automated health information data.
Haque R, Shi J, Schottinger JE, Ahmed SA, Chung J, Avila C, Lee VS, Cheetham TC, Habel LA, Fletcher SW, Kwan ML
Med Care. 2015; 53:380-5 PubMed Abstract

Association of body mass index and prostate cancer mortality.
Haque R, Van Den Eeden SK, Wallner LP, Richert-Boe K, Kallakury B, Wang R, Weinmann S
Obes Res Clin Pract. 2014; 8:e374-81 PubMed Abstract

Adherence to endocrine therapy in breast cancer adjuvant and prevention settings.
Chlebowski RT, Kim J, Haque R
Cancer Prev Res (Phila). 2014; 7:378-87 PubMed Abstract

Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.
Jordan JH, Thwin SS, Lash TL, Buist DS, Field TS, Haque R, Pawloski PA, Petersen HV, Prout MN, Quinn VP, Yood MU, Silliman RA, Geiger AM
Breast Cancer Res Treat. 2014; 146:401-9 PubMed Abstract

Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK
J Clin Oncol. 2014; 32:1324-30 PubMed Abstract

Comorbidities and cardiovascular disease risk in older breast cancer survivors.
Haque R, Prout M, Geiger AM, Kamineni A, Thwin SS, Avila C, Silliman RA, Quinn V, Yood MU
Am J Manag Care. 2014; 20:86-92 PubMed Abstract

Fracture risk in older, long-term survivors of early-stage breast cancer.
Pawloski PA, Geiger AM, Haque R, Kamineni A, Fouayzi H, Ogarek J, Petersen HV, Bosco JL, Thwin SS, Silliman RA, Field TS
J Am Geriatr Soc. 2013; 61:888-95 PubMed Abstract

Immunohistochemical Expression of ERG in the Molecular Epidemiology of Fatal Prostate Cancer Study.
Weinmann S, Van Den Eeden SK, Haque R, Chen C, Richert-Boe K, Schwartzman J, Gao L, Berry DL, Kallakury BV, Alumkal JJ
Prostate. 2013 PubMed Abstract

Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies.
Wallner LP, Wang R, Jacobsen SJ, Haque R
Cancer Epidemiol Biomarkers Prev. 2013; 22:313-6 PubMed Abstract

Sleep disturbance, inflammation and depression risk in cancer survivors.
Irwin MR, Olmstead RE, Ganz PA, Haque R
Brain Behav Immun. 2013; 30 Suppl:S58-67 PubMed Abstract

Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.
Collins LC, Achacoso N, Haque R, Nekhlyudov L, Fletcher SW, Quesenberry CP, Schnitt SJ, Habel LA
Breast Cancer Res Treat. 2013; 139:453-60 PubMed Abstract

Impact of type 2 diabetes on lower urinary tract symptoms in men: a cohort study.
Van Den Eeden SK, Ferrara A, Shan J, Jacobsen SJ, Quinn VP, Haque R, Quesenberry CP
BMC Urol. 2013; 13:12 PubMed Abstract

Preventive care and health behaviors among overweight/obese men in HMOs.
Quinn VP, Jacobsen SJ, Slezak JM, Van Den Eeden SK, Caan B, Sternfeld B, Haque R
Am J Manag Care. 2012; 18:25-32 PubMed Abstract

Ten-Year Risk of Diagnostic Mammograms and Invasive Breast Procedures After Breast-Conserving Surgery for DCIS.
Nekhlyudov L, Habel LA, Achacoso N, Jung I, Haque R, Collins LC, Schnitt SJ, Quesenberry CP, Fletcher SW
J Natl Cancer Inst. 2012; 104:614-21 PubMed Abstract

Validation of AJCC TNM staging for breast tumors diagnosed before 2004 in cancer registries.
Kwan ML, Haque R, Lee VS, Joanie Chung WL, Avila CC, Clancy HA, Quinn VP, Kushi LH
Cancer Causes Control. 2012; 23:1587-1591 PubMed Abstract

A comparison of lifestyle and behavioral cardiovascular disease risk factors between Asian Indian and White non-Hispanic men.
Ghai NR, Jacobsen SJ, Van Den Eeden SK, Ahmed AT, Haque R, Rhoads GG, Quinn VP
Ethn Dis. 2012; 22:168-74 PubMed Abstract

Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades.
Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF
Cancer Epidemiol Biomarkers Prev. 2012; 21:1848-55 PubMed Abstract

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
Haque R, Ahmed SA, Fisher A, Avila CC, Shi J, Guo A, Craig Cheetham T, Schottinger JE
Cancer Med. 2012; 1:318-27 PubMed Abstract

Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma.
Chao C, Silverberg MJ, Martínez-Maza O, Chi M, Abrams DI, Haque R, Zha HD, McGuire M, Xu L, Said J
Clin Cancer Res. 2012; 18:4702-12 PubMed Abstract

Evaluating racial/ethnic disparities in lower urinary tract symptoms in men.
Van Den Eeden SK, Shan J, Jacobsen SJ, Aaronsen D, Haque R, Quinn VP, Quesenberry CP, Urologic Diseases in America Project
J Urol. 2012; 187:185-9 PubMed Abstract

Long-term safety of radiotherapy and breast cancer laterality in older survivors.
Haque R, Yood MU, Geiger AM, Kamineni A, Avila CC, Shi J, Silliman RA, Quinn VP
Cancer Epidemiol Biomarkers Prev. 2011; 20:2120-6 PubMed Abstract

Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction.
Gleason JM1, Slezak JM, Jung H, Reynolds K, Van den Eeden SK, Haque R, Quinn VP, Loo RK, Jacobsen SJ
J Urol. 2011; 185:1388-93 PubMed Abstract

Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study.
Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP, Caan BJ, Van Den Eeden SK
PLoS One. 2010; 5:e8736 PubMed Abstract

Red wine consumption and risk of prostate cancer: the California men's health study.
Chao C, Haque R, Van Den Eeden SK, Caan BJ, Poon KY, Quinn VP
Int J Cancer. 2010; 126:171-9 PubMed Abstract

Red wine consumption not associated with reduced risk of colorectal cancer.
Chao C, Haque R, Caan BJ, Poon KY, Tseng HF, Quinn VP
Nutr Cancer. 2010; 62:849-855 PubMed Abstract

Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans.
Haque R, Achacoso NS, Fletcher SW, Nekhlyudov L, Collins LC, Schnitt SJ, Quesenberry CP, Habel LA
Am J Manag Care. 2010; 16:351-60 PubMed Abstract

A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies.
Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL
J Clin Epidemiol. 2010; 63:64-74 PubMed Abstract

Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery.
Nekhlyudov L, Habel LA, Achacoso NS, Jung I, Haque R, Collins LC, Schnitt SJ, Quesenberry CP, Fletcher SW
J Clin Oncol. 2009; 27:3211-6 PubMed Abstract

Breast cancer recurrence in older women five to ten years after diagnosis.
Bosco JL, Lash TL, Prout MN, Buist DS, Geiger AM, Haque R, Wei F, Silliman RA, BOW Investigators
Cancer Epidemiol Biomarkers Prev. 2009; 18:2979-83 PubMed Abstract

Correlates of prostate-specific antigen testing in a large multiethnic cohort.
Haque R, Van Den Eeden SK, Jacobsen SJ, Caan B, Avila CC, Slezak J, Sternfeld B, Loo RK, Quinn VP
Am J Manag Care. 2009; 15:793-9 PubMed Abstract

Generational status and duration of residence predict diabetes prevalence among Latinos: the California Men's Health Study.
Ahmed AT, Quinn VP, Caan B, Sternfeld B, Haque R, Van Den Eeden SK
BMC Public Health. 2009; 9:392 PubMed Abstract

Statin Use and Risk of Colorectal Cancer in a Cohort of Middle-Aged Men in the US: A Prospective Cohort Study.
Flick ED, Habel LA, Chan KA, Haque R, Quinn VP, Van Den Eeden SK, Sternfeld B, Orav EJ, Seeger JD, Quesenberry CP, Caan BJ
Drugs. 2009; 69:1445-57 PubMed Abstract

Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients.
Collins LC, Achacoso N, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP, Puligandla B, Alshak NS, Goldstein LC, Gown AM, Schnitt SJ, Habel LA
Am J Surg Pathol. 2009; 33:1802-8 PubMed Abstract

Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.
Aiello EJ, Buist DS, Wagner EH, Tuzzio L, Greene SM, Lamerato LE, Field TS, Herrinton LJ, Haque R, Hart G, Bischoff KJ, Geiger AM
Breast Cancer Res Treat. 2008; 107:397-403 PubMed Abstract

Abstracting height and weight from medical records, and breast cancer pathologic factors.
McEligot AJ, Im T, Dillman RO, West JG, Salem R, Haque R, Anton-Culver H
Cancer Causes Control. 2008 PubMed Abstract

Correlates of screening sigmoidoscopy use among men in a large nonprofit health plan.
Haque R, Quinn VP, Habel LA, Enger SM, Sternfeld B, Van Den Eeden SK, Sadler M, Chiu V, Caan B
Cancer. 2007; 110:275-81 PubMed Abstract

Children's intellectual function in relation to arsenic exposure.
von Ehrenstein OS, Poddar S, Yuan Y, Mazumder DG, Eskenazi B, Basu A, Hira-Smith M, Ghosh N, Lahiri S, Haque R, Ghosh A, Kalman D, Das S, Smith AH
Epidemiology. 2007; 18:44-51 PubMed Abstract

Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients.
Collins LC, Achacoso NA, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP, Alshak NS, Puligandla B, Brodsky GL, Schnitt SJ, Habel LA
Mod Pathol. 2007; 20:1149-55 PubMed Abstract

Statin use and risk of prostate cancer in the California Men's Health Study cohort.
Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP, Sternfeld B, Jacobsen SJ, Whitmer RA, Caan BJ
Cancer Epidemiol Biomarkers Prev. 2007; 16:2218-25 PubMed Abstract

Impact of Bariatric Surgery on Cancer Incidence in Severely Obese Adults

Reina Haque, PhD, MPH, Co-Investigator

Funding source:

The goal of this project is to estimate the impact of bariatric surgery versus routine non-surgical care on the incidence of cancer (all types) in all severely obese patients (men and women).

Chronic Myelogenous Leukemia and Outcomes of Tyrosine Kinase Inhibitor Therapy

Reina Haque, PhD, MPH, Principal Investigator

Funding source:

The aim of this investigation initiated retrospective cohort study are to examine long-term health effects in the cohort of CML and determine if health effects vary by drug adherence to TKIs.

https://www.ncbi.nlm.nih.gov/pubmed/28259737

Biobehavioral Vulnerability to Accelerated Aging in Breast Cancer Survivors

Reina Haque, PhD, MPH, Site Principal Investigator

Funding source: American Cancer Society

The aim of this project is to examine cellular and genomic markers of inflammation, telomere erosion, telomere length, and microarray data of 300 breast cancer survivors and comparison women who are enrolled in the KPSC-UCLA collaborative STRIVE1 and STRIVE2 studies.

Observational Study of the Epidemiology in Clinical Outcomes of Breast Cancer in Women with BRCA Mutations

Reina Haque, PhD, MPH, Principal Investigator

Funding source: AstraZeneca

This cohort study examines the long-term clinical outcomes of women with breast cancer who are BRCA mutation carriers.

http://www.thepermanentejournal.org/issues/2018/fall/6881-breast-cancer.html

Cardiovascular toxicity following aromatase inhibitor use

Reina Haque, PhD, MPH, Principal Investigator

Funding source: California Breast Cancer Research Program (CBCRP)

The aim of this cohort is to assess the risk of cardiovascular disease associated with endocrine treatments for breast cancer.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2513898; https://link.springer.com/article/10.1007%2Fs10549-018-05086-8; www.ncbi.nlm.nih.gov/pmc/articles/PMC4565775/

Use of Multiple Biomarkers with the Risk of Ovarian Cancer Algorithm (ROCA) for Early Detection of Ovarian Cancer in Female Carriers of BRCA1 and BRCA2 mutations

Reina Haque, PhD, MPH, Co-Investigator

Funding source: Garfield Memorial Fund

The goal of this prospective recruitment study is to determine if ovarian cancer screening is enhanced by more frequent biomarker testing (CA125 & HE4) versus usual testing frequency in women with BRCA1/2 mutations.

Sleep Inflammation and Depression Occurrence in Breast Cancer Survivors (STRIVE1)

Reina Haque, PhD, MPH, Site Principal Investigator

Funding source: National Cancer Institute (NCI)

The aim of this prospective study is to examine the association between sleep disturbance, cellular and genomic markers of inflammation, and depression occurrence in breast cancer survivors.

Sleep Disturbance, Inflammation & Cellular Aging in Breast Cancer Survivors (STRIVE 2)

Reina Haque, PhD, MPH, Principal Investigator

Funding source: National Cancer Institute (NCI)

The goal of this prospective recruitment study is to evaluate longitudinal differences in the rates of change in inflammation and telomere erosion in breast cancer survivors vs. non-cancer comparison women to determine if such molecular changes are due to cancer biology, or its treatment, or consequences of aging.

REPRISE 2: Is depression associated with prostate cancer progression?

Reina Haque, PhD, MPH, Principal Investigator

Funding source: National Cancer Institute (NCI)

This study examines if depression and its treatment can affect the course of prostate cancer.

Risk of Cancer in Childhood and Adolescence Associated with Medical Imaging

Reina Haque, PhD, MPH, Principal Investigator

Funding source: National Cancer Institute (NCI)

Funding Years: 2015-2020

The goal of this study it to evaluate patterns of medical imaging associated with cumulative exposure to radiation (CT, nuclear medicine, fluoroscopy, angiography, and radiography), and subsequent risk of childhood cancers.

Antidepressants and Breast Cancer Pharmacoepidemiology

Reina Haque, PhD, MPH, Principal Investigator

Funding source: National Cancer Institute (NCI)

Funding Years: 2010-2014

This study examines drug interactions between tamoxifen and antidepressants in nearly 23,000 breast cancer survivors diagnosed with early stage disease in the two largest health plans in California.

Treatment patterns of ductal carcinoma in situ (DCIS) across multiple KP regions

Reina Haque, PhD, MPH, Principal Investigator

Funding source: Kaiser Permanente

Funding Years: 2013-2013

The goal is to examine treatment patterns of DCIS across KP managed care organizations nationwide.

Racial/Ethnic and Socioeconomic Status Disparities in Quality of Breast Cancer Systemic Therapy

Reina Haque, PhD, MPH, Principal Investigator

Funding source: National Cancer Institute (NCI)

Funding Years: 2012-2014

The major aim of this retrospective-SEER based cohort study is to determine the underlying reasons for observed patterns and correlates of quality adjuvant chemotherapy and hormonal therapy

OPATS: Outcomes of Prostate Cancer Androgen Deprivation Therapy Study

Reina Haque, PhD, MPH, Principal Investigator

Funding source: National Cancer Institute (NCI)

Funding Years: 2010-2014

The goal is to assess fatal and morbid outcomes up to 15 years following androgen deprivation therapy for men initially diagnosed with localized prostate cancer.

Print Page

Research Scientists

Select one of Our
Scientists to find out
their latest research.

Site Map
FAQ
Contact Us